- Home
- GWRS vs FHTX Comparison
GWRS vs FHTX Comparison
Compare GWRS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GWRS | FHTX |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | United States |
| Employees | 129 | N/A |
| Industry | Water Supply | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.7M | 323.4M |
| IPO Year | 2008 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GWRS | FHTX |
|---|---|---|
| Price | $7.12 | $4.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.20 | ★ $11.50 |
| AVG Volume (30 Days) | 79.2K | ★ 121.3K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,914,000.00 | $30,909,000.00 |
| Revenue This Year | $15.29 | $8.89 |
| Revenue Next Year | $8.28 | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 8.51 | ★ 36.75 |
| 52 Week Low | $6.55 | $3.27 |
| 52 Week High | $11.17 | $6.95 |
Technical Indicators
Market Signals| Indicator | GWRS | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 44.98 |
| Support Level | $7.19 | $3.65 |
| Resistance Level | $7.82 | $5.82 |
| Average True Range (ATR) | 0.22 | 0.27 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 98.77 | 49.80 |
Price Performance
Historical ComparisonAbout GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix and Tucson, Arizona. It operates within the State of Arizona. Operating revenue of the company is derived from regulated water, wastewater, and recycled water service provided to customers based upon tariff rates.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.